Dr. Kiran K. Yalamanchili, MD | Lubbock ...

Dr. Kiran K. Yalamanchili

Claim this profile

Covenant Medical Center-Lakeside

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
7 reported clinical trials
52 drugs studied

Area of expertise

1

Lung Cancer

Kiran K. Yalamanchili has run 2 trials for Lung Cancer. Some of their research focus areas include:

ALK negative
PD-L1 positive
EGFR negative
2

Non-Small Cell Lung Cancer

Kiran K. Yalamanchili has run 2 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:

PD-L1 positive
Stage IV
ALK negative

Affiliated Hospitals

Image of trial facility.

Covenant Medical Center-Lakeside

Image of trial facility.

Joe Arrington Cancer Research And Treatment Center

Clinical Trials Kiran K. Yalamanchili is currently running

Image of trial facility.

Chemotherapy + Radiation Therapy

for Head and Neck Cancer

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab.

Recruiting

1 award

Phase 2 & 3

21 criteria

Image of trial facility.

Targeted Therapy

for Solid Tumors

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.

Recruiting

1 award

Phase 2

17 criteria

More about Kiran K. Yalamanchili

Clinical Trial Related

6 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 3 Active Clinical Trials

Treatments Kiran K. Yalamanchili has experience with

  • Cisplatin
  • Atezolizumab
  • Intensity-Modulated Radiation Therapy
  • Nivolumab
  • Ipilimumab
  • Lenvatinib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Kiran K. Yalamanchili specialize in?

Is Kiran K. Yalamanchili currently recruiting for clinical trials?

Are there any treatments that Kiran K. Yalamanchili has studied deeply?

What is the best way to schedule an appointment with Kiran K. Yalamanchili?

What is the office address of Kiran K. Yalamanchili?

Is there any support for travel costs?